SVRA — Savara Inc. stock price, charts and financials

Latest market price

5.41

+0.08+1.50%

Overview Short InterestFilings

SVRAQT77Savara Inc.·NASDAQ

Overview Short InterestFilings

5.41+1.50%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 STOK+7.14%$31.67 TSHA+7.27%$6.20 AUPH+2.47%$14.93 MESO+2.28%$14.80 URGN+3.45%$39.92 TYRA+1.53%$32.53 IOVA+0.93%$4.36

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	204.93M	Perf Week	-1.84%

Market Cap	1.09B	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-0.15%	Shs Float	106.86M	Perf Month	-14.31%

Enterprise Value	919.26M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	31.95%	Perf Quarter	4.10%

Income	-119.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	21.12	Perf Half Y	-1.30%

Sales	0.00	P/B	6.21	EPS next Y	44.73%	ROA	-58.42%	Short Interest	34.14M	Perf YTD	-11.61%

Book/sh	0.86	P/C	5.38	EPS next 5Y	-	ROE	-87.19%	52W High	7.12 -23.97%	Perf Year	105.79%

Cash/sh	0.99	P/FCF	-	EPS past 3/5Y	-	ROIC	-65.06%	52W Low	2.47 119.34%	Perf 3Y	62.50%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	4.77% 5.03%	Perf 5Y	306.87%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-16.67%	Oper. Margin	0.00%	ATR (14)	0.28	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	13.47	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	42.29	Recom	2.18

Dividend Gr. 3/5Y	-	Current Ratio	13.47	EPS Q/Q	-25.00%	SMA20	-6.33%	Beta	0.25	Target Price	10.00

Payout	0.00%	Debt/Eq	0.15	Sales Q/Q	-	SMA50	-3.99%	Rel Volume	0.95	Prev Close	5.33

Employees	70	LT Debt/Eq	0.15	Earnings	Aug 12	SMA200	-1.62%	Avg Volume	1.73M	Price	5.41

IPO Date	Apr 28, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.11% -	Net Debt/EBITDA	0.07	Volume	1,638,725	Change	1.50%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Mar-16-26	Reiterated	William Blair		$10
Dec-23-25	Reiterated	Oppenheimer	Outperform	$11 → $10
Dec-23-25	Reiterated	UBS		$10
Oct-23-25	Reiterated	JMP Securities	Market Outperform	$9.00 → $11
Sep-09-25	Reiterated	Guggenheim	Buy	$10 → $11
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$10 → $5.00
May-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-24	Downgrade	Evercore ISI Group	Outperform → In Line
Aug-13-24	Reiterated	JMP Securities	Market Outperform	$10 → $9.00
Jun-27-24	Reiterated	JMP Securities	Market Outperform	$10

Latest News

Jul-30-26

Jul-30-2608:05AM

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041businesswire.com

Jul-22-26

Jul-22-2610:26AM

Here's Why You Should Add Savara Stock to Your Portfolio Nowzacks.com

Jun-27-26

Jun-27-2611:14AM

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timelinefool.com

Company

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	78	44	28	29	35	39	1	0
Gross Profit	0	-78	-44	-28	-29	-35	-39	-1	0
Selling, General and Administrative Excl. Other	42	25	16	11	12	12	13	11	11
Research and Development	81	78	44	28	29	35	39	37	19
Other Operating Expense	0	-78	-44	-28	-29	-32	-12	0	0
Operating Income	-124	-103	-60	-39	-41	-49	-79	-70	-30
Interest Expense	0	0	0	0	2	1	0	0	1
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	5	7	5	1	1	1	1	0	-2
Net Income Before Taxes	-119	-96	-55	-38	-43	-50	-78	-70	-33
Income Taxes	0	0	0	0	0	0	0	-9	-4
Consolidated Net Income	-119	-96	-55	-38	-43	-50	-78	-62	-30
Net Income From Continuing Operations	-119	-96	-55	-38	-43	-50	-78	-62	-30
Net Income	-119	-96	-55	-38	-43	-50	-78	-62	-30
EPS (Recurring)	-0.53	-0.48	-0.33	-0.25	-0.32	-0.84	-2.62	-1.85	-1.70
EPS (Basic, Before Extraordinaries)	-0.53	-0.48	-0.33	-0.25	-0.32	-0.84	-2.62	-1.85	-1.70
EPS (Diluted)	-0.53	-0.48	-0.33	-0.25	-0.32	-0.84	-2.62	-1.85	-1.70
EBITDA	-119	-102	-59	-38	-40	-46	-50	-70	-32
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	222	198	165	153	134	59	40	33	18
Market Capitalization	1,339	608	776	237	166	68	179	250	267
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lowrance David L	Chief Financial Officer	Jun 22 '26	Option Exercise	1.76	580,187	1,021,117	983,947	Jun 22
Lowrance David L	Chief Financial Officer	Jun 22 '26	Sale	5.68	394,528	2,241,432	536,032	Jun 22
Lowrance David L	Chief Financial Officer	Mar 18 '26	Option Exercise	1.60	366,747	588,456	552,550	Mar 20
McCracken Joseph S	Director	Feb 16 '26	Option Exercise	1.76	1,807	3,180	302,644	Feb 17
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04
Hawkins Richard J	Director	Nov 14 '25	Option Exercise	1.46	5,860	8,556	121,326	Nov 17
Hawkins Richard J	Director	Jun 20 '25	Buy	2.04	48,225	98,572	115,466	Jun 23
McCracken Joseph S	Director	May 29 '25	Buy	2.08	10,000	20,825	260,837	Jun 02
RAMSAY DAVID A	Director	Mar 31 '25	Buy	2.77	150,000	416,250	2,513,642	Apr 01
Pauls Matthew	CHIEF EXECUTIVE OFFICER	Dec 16 '24	Sale	3.31	54,702	180,828	1,536,379	Dec 16
Lowrance David L	Chief Financial Officer	Dec 16 '24	Sale	3.33	25,000	83,278	381,005	Dec 16
Hawkins Richard J	Director	Dec 16 '24	Sale	3.32	8,000	26,569	67,241	Dec 16
McCracken Joseph S	Director	Nov 19 '24	Buy	2.95	20,000	59,072	210,837	Nov 20
RAMSAY DAVID A	Director	Nov 18 '24	Buy	2.88	100,000	287,600	2,323,642	Nov 18

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.